Alison R. Walker

Hematology | Oncology

12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: June 15, 2026

BPI26-015: Complementing NCCN Guidelines With a Clinician-Guided AI Reasoning Platform: Evaluation of The BlueScrubs.

BPI26-015: Complementing NCCN Guidelines With a Clinician-Guided AI Reasoning Platform: Evaluation of The BlueScrubs.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Journal: Annals of hematology

Published: April 02, 2026

BPI26-015: Complementing NCCN Guidelines With a Clinician-Guided AI Reasoning Platform: Evaluation of The BlueScrubs.

BPI26-015: Complementing NCCN Guidelines With a Clinician-Guided AI Reasoning Platform: Evaluation of The BlueScrubs.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial.

Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial.

Journal: Cancers

Published: November 03, 2025

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

Journal: Blood neoplasia

Published: September 08, 2025

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.

Journal: Blood cancer discovery

Published: June 03, 2025

Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival.

Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 23, 2025

Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML).

Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML).

Journal: Leukemia research

Published: October 15, 2024

A comparative assessment of molecular-based prognostic models in CMML.

A comparative assessment of molecular-based prognostic models in CMML.

Journal: Blood neoplasia

Published: September 09, 2024

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm.

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm.

Journal: Blood neoplasia

Published: August 22, 2024

Novel therapies upon failure of HMA plus venetoclax.

Novel therapies upon failure of HMA plus venetoclax.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 09, 2023

Showing 1-12 of 75

Last Updated: 09/26/2026